Redeye retains its positive view of Sdiptech following a stable Q1 report. While we think Q2 will be similar as Q1 with muted organic profit growth, we think the prospects for a return to organic profit growth are brighter from the second half of 2025 and onwards. We keep our base case fair value per share intact and views stable quarterly reports along with acquisitions to be primary catalysts for the depressed share price.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/